Skip to main content
. Author manuscript; available in PMC: 2021 Sep 16.
Published in final edited form as: Arch Pathol Lab Med. 2020 Nov 1;144(11):1392–1396. doi: 10.5858/arpa.2019-0447-OA

Table 1.

Summary of Clinical Features of the 6 Patients

Patient No. Age, y/Sex Cancer Diagnosis Clinical History I/O Medication Time to First Symptoms, da Outcome

1 53/F Lymphoma DM, hypertension, dyslipidemia Atezolizumab 19 Resolution, 17 d
2 70/M Hepatocellular DM Pembrolizumab 6 Resolution, 2 mo
3 75/F Endometrial carcinoma No significant history Tremelimumab, durvalumab 21 Resolution, 14 d
4 71/M Melanoma No significant history Nivolumab, ipilimumab 7 Death (heart failure, multisystem organ failure)
5 75/M Pancreatic carcinoma DM, hypertension, dyslipidemia Nivolumab 38 Resolution (partial), 20 d
6 83/F Melanoma Hypothyroidism, hypertension, dyslipidemia, COPD Nivolumab 21 Resolution, 7 d

Abbreviations: COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; I/O, immune oncology.

a

After last dose of immune-oncology agent.